--- title: "Electrocore | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 9.584 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285431975.md" datetime: "2026-05-06T20:23:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285431975.md) - [en](https://longbridge.com/en/news/285431975.md) - [zh-HK](https://longbridge.com/zh-HK/news/285431975.md) --- # Electrocore | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 9.584 M Revenue: As of FY2026 Q1, the actual value is USD 9.584 M, beating the estimate of USD 9.011 M. EPS: As of FY2026 Q1, the actual value is USD -0.59, beating the estimate of USD -0.612. EBIT: As of FY2026 Q1, the actual value is USD -5.05 M. ### Financial Performance Summary #### Net Sales electroCore, Inc. reported net sales of $9.6 million for the first quarter of 2026, marking a 43% increase compared to $6.7 million in the first quarter of 2025 . **Total Net Sales:** $9,584 thousand for Q1 2026, up from $6,719 thousand for Q1 2025 . **United States – Rx:** $7,421 thousand for Q1 2026, compared to $5,005 thousand for Q1 2025 . **General Wellness:** $1,588 thousand for Q1 2026, compared to $1,106 thousand for Q1 2025 . **Outside the United States:** $502 thousand for Q1 2026, compared to $498 thousand for Q1 2025 . **TAC-STIM:** $42 thousand for Q1 2026, down from $90 thousand for Q1 2025 . **In-License / Other:** $31 thousand for Q1 2026, compared to $20 thousand for Q1 2025 . #### Cost of Goods Sold - Q1 2026: $1,220 thousand . - Q1 2025: $1,013 thousand . #### Gross Profit and Margin Gross profit increased by $2.7 million to $8.4 million for the three months ended March 31, 2026, from $5.7 million for the same period in 2025 . Gross margin expanded to 87% for Q1 2026, up from 85% in the prior year period . #### Operating Expenses - **Research and development expense:** $740 thousand for Q1 2026, compared to $642 thousand for Q1 2025 . - **Selling, general and administrative expense:** $12,940 thousand for Q1 2026, compared to $8,886 thousand for Q1 2025 . Sales and marketing increased by $1.8 million from the prior year . General and administrative expense increased by $2.3 million from the prior year, including approximately $1.9 million of one-time leadership transition expenses and $0.3 million of legal fees . - **Total operating expenses:** $13,680 thousand for Q1 2026, compared to $9,528 thousand for Q1 2025 . #### Loss from Operations Loss from operations was - $5,316 thousand for Q1 2026, compared to - $3,822 thousand for Q1 2025 . #### Other (income) expense - **Interest and other income:** - $52 thousand for Q1 2026, compared to - $83 thousand for Q1 2025 . - **Interest expense:** $318 thousand for Q1 2026, compared to $5 thousand for Q1 2025 . - **Other expense:** $10 thousand for Q1 2026, compared to $159 thousand for Q1 2025 . - **Total other expense:** $276 thousand for Q1 2026, compared to $81 thousand for Q1 2025 . #### Loss before income taxes Loss before income taxes was - $5,592 thousand for Q1 2026, compared to - $3,903 thousand for Q1 2025 . #### Benefit from income taxes Benefit from income taxes was $321 thousand for Q1 2026, compared to $48 thousand for Q1 2025 . #### Net Loss GAAP net loss for the first quarter of 2026 was - $5.3 million (or - $5,271 thousand), compared to - $3.9 million (or - $3,855 thousand) in the first quarter of 2025 . The increase in GAAP net loss was primarily due to $1.9 million of one-time expenses related to leadership transition . #### Adjusted EBITDA Net Loss Adjusted EBITDA net loss improved by 24% year-over-year to - $2.3 million for Q1 2026, compared to - $3.1 million in Q1 2025 . #### Cash, Cash Equivalents, and Marketable Securities Total cash, cash equivalents, and marketable securities were approximately $8.8 million at March 31, 2026, down from approximately $11.6 million at December 31, 2025 . #### Operational Metrics VA prescription gammaCore revenue grew approximately 26% year-over-year . The number of VA facilities purchasing prescription gammaCore products increased to 200, up from 175 a year ago . Approximately 15,000 VA patients have received a gammaCore device, representing about 2.5% penetration of the estimated addressable VA headache market . Sales of the Quell product line exceeded $1.0 million in quarterly revenue for the first time in Q1 2026, with cumulative Quell revenue reaching approximately $2.7 million since its acquisition in May 2025 . Truvaga revenue grew approximately 38% year-over-year to $1.5 million, and its return on advertising spend (ROAS) improved approximately 14% sequentially to about 2.37x . #### Outlook / Guidance For the full year of 2026, electroCore, Inc. is reaffirming its revenue guidance for approximately 30% annual revenue growth over 2025 . The company expects to launch Quell Relief for lower extremity pain later in the second half of 2026 . electroCore, Inc. anticipates that the majority of fiscal year 2026 revenue will continue to come from the VA . ### Related Stocks - [ECOR.US](https://longbridge.com/en/quote/ECOR.US.md) ## Related News & Research - [electroCore Touts 30% Growth Outlook, VA Opportunity at LD Micro Conference](https://longbridge.com/en/news/287020276.md) - [electroCore reiterates FY 2026 revenue guidance](https://longbridge.com/en/news/285435196.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)